CN1183129C - 作为加压素激动剂的稠合氮杂� - Google Patents

作为加压素激动剂的稠合氮杂� Download PDF

Info

Publication number
CN1183129C
CN1183129C CNB018031323A CN01803132A CN1183129C CN 1183129 C CN1183129 C CN 1183129C CN B018031323 A CNB018031323 A CN B018031323A CN 01803132 A CN01803132 A CN 01803132A CN 1183129 C CN1183129 C CN 1183129C
Authority
CN
China
Prior art keywords
compound
pharmaceutically useful
useful salt
methyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018031323A
Other languages
English (en)
Chinese (zh)
Other versions
CN1392875A (zh
Inventor
Dm
D·M·阿施沃斯
W��Ƥ��
G·R·W·皮特
���˹���Ѷ���
P·哈德逊
�Ү��
C·M·耶
R·J·弗兰克林
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring BV filed Critical Ferring BV
Publication of CN1392875A publication Critical patent/CN1392875A/zh
Application granted granted Critical
Publication of CN1183129C publication Critical patent/CN1183129C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB018031323A 2000-01-05 2001-01-04 作为加压素激动剂的稠合氮杂� Expired - Fee Related CN1183129C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0000079.4A GB0000079D0 (en) 2000-01-05 2000-01-05 Novel antidiuretic agents
GB0000079.4 2000-01-05

Publications (2)

Publication Number Publication Date
CN1392875A CN1392875A (zh) 2003-01-22
CN1183129C true CN1183129C (zh) 2005-01-05

Family

ID=9883168

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018031323A Expired - Fee Related CN1183129C (zh) 2000-01-05 2001-01-04 作为加压素激动剂的稠合氮杂�

Country Status (34)

Country Link
US (3) US7074781B2 (enExample)
EP (1) EP1248784B1 (enExample)
JP (2) JP3869723B2 (enExample)
KR (1) KR100605466B1 (enExample)
CN (1) CN1183129C (enExample)
AR (1) AR035327A1 (enExample)
AT (1) ATE366730T1 (enExample)
AU (1) AU777538B2 (enExample)
BR (1) BR0107414B1 (enExample)
CA (1) CA2396277C (enExample)
CY (1) CY1108034T1 (enExample)
CZ (1) CZ303444B6 (enExample)
DE (1) DE60129298T2 (enExample)
DK (1) DK1248784T3 (enExample)
EE (1) EE200200367A (enExample)
ES (1) ES2288923T3 (enExample)
GB (1) GB0000079D0 (enExample)
HK (1) HK1046910B (enExample)
HR (1) HRP20020481B1 (enExample)
HU (1) HU229937B1 (enExample)
IL (1) IL149528A0 (enExample)
MX (1) MXPA02006546A (enExample)
MY (1) MY140467A (enExample)
NO (1) NO322571B1 (enExample)
NZ (1) NZ518803A (enExample)
PL (1) PL211341B1 (enExample)
PT (1) PT1248784E (enExample)
RU (1) RU2259367C2 (enExample)
SI (1) SI1248784T1 (enExample)
SK (1) SK287005B6 (enExample)
UA (1) UA73152C2 (enExample)
UY (1) UY26521A1 (enExample)
WO (1) WO2001049682A1 (enExample)
ZA (1) ZA200205180B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5803659A (en) 1995-12-08 1998-09-08 Chattey; Nigel Modular caissons for use in constructing, expanding and modernizing ports and harbors.
US7138393B2 (en) 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
GB0000079D0 (en) * 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
AU2001252222B2 (en) * 2000-03-27 2006-11-02 Merck Serono Sa Pharmaceutically active pyrrolidine derivatives as bax inhibitors
EA006424B1 (ru) * 2000-03-27 2005-12-29 Апплайд Резеч Системз Арс Холдинг Н.В. Фармацевтически активные производные пирролидина
GB0015601D0 (en) 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents
GB0115515D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Oxytocin agonisys
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
NZ542815A (en) 2003-04-28 2009-01-31 Astellas Pharma Inc 4,4-Difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or salt thereof
DE60305043T2 (de) * 2003-11-13 2006-11-30 Ferring B.V. Blisterverpackung und feste Dosierungsform enthaltend Desmopressin
EP1813603A1 (en) * 2004-11-17 2007-08-01 Kissei Pharmaceutical Co., Ltd. Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both
JP5009785B2 (ja) * 2005-03-25 2012-08-22 キッセイ薬品工業株式会社 ウレア誘導体、それを含有する医薬組成物およびそれらの医薬用途
WO2007052517A1 (ja) * 2005-10-31 2007-05-10 Sumitomo Chemical Company, Limited ヒドロキシ－２－ピロリジンカルボキシアミド化合物の製法
WO2008038600A1 (en) * 2006-09-25 2008-04-03 Kissei Pharmaceutical Co., Ltd. 1,4-benzodiazepine derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes
CN101686983A (zh) * 2007-05-10 2010-03-31 Amr科技公司 芳基和杂芳基取代的四氢苯并-1,4-二氮杂䓬及其阻断去甲肾上腺素、多巴胺和5-羟色胺重摄取的用途
RU2472539C2 (ru) 2007-08-06 2013-01-20 Аллерган, Инк. Способы и устройства для доставки препарата десмопрессина
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
DK3225250T3 (da) * 2008-05-21 2019-11-04 Ferring Bv Orodispersibel desmopressin til forlængelse af den indledende søvnperiode, som ikke forstyrres af nykturi
GB201005623D0 (en) 2010-04-01 2010-05-19 Vantia Ltd New polymorph
GB201105537D0 (en) * 2011-03-31 2011-05-18 Vantia Ltd New process
WO2020154581A1 (en) 2019-01-24 2020-07-30 Assia Chemical Industries Ltd Solid state forms of fedovapagon-salicyclic acid co-crystal

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960886A (en) 1968-07-03 1976-06-01 Sterling Drug Inc. Substituted N-arylanilines
CH599752A5 (enExample) 1973-04-18 1978-05-31 Ciba Geigy Ag
CA1047490A (en) 1973-04-18 1979-01-30 Friedrich Karrer Ethers
DE2355454A1 (de) 1973-11-07 1976-10-07 Paul Geisslinger Lochmaschine
EP0186817B1 (en) 1984-12-10 1989-08-02 Nissan Chemical Industries Ltd. 3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it
WO1991005549A1 (en) 1989-10-20 1991-05-02 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
US5753677A (en) 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
CA2066104C (en) 1991-04-19 2003-05-27 Hidenori Ogawa Benzazepine derivatives as vasopressin antagonists
JPH05320135A (ja) * 1992-05-19 1993-12-03 Yamanouchi Pharmaceut Co Ltd テトラヒドロベンズアゼピン誘導体
US5498609A (en) 1992-08-20 1996-03-12 Otsuka Pharmaceutical Company, Limited Benzoazepinyl compounds as oxytocin and vasopressin antagonists
TW270927B (enExample) * 1992-10-16 1996-02-21 Otsuka Pharma Co Ltd
WO1994012476A1 (fr) * 1992-11-25 1994-06-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de benzanilide
WO1994020473A1 (fr) * 1993-03-11 1994-09-15 Yamanouchi Pharmaceutical Co., Ltd. Compose avec action antagoniste de la vasopressine
GB9307527D0 (en) 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
US5760031A (en) 1993-07-29 1998-06-02 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5968930A (en) 1993-07-29 1999-10-19 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5516774A (en) 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5843952A (en) 1993-07-29 1998-12-01 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US6403577B1 (en) * 1993-11-17 2002-06-11 Eli Lilly And Company Hexamethyleneiminyl tachykinin receptor antagonists
FI1215U1 (fi) * 1993-12-03 1994-02-21 Valmet Paper Machinery Inc Anlaeggning i samband med styrningen av en vira
FR2716194B1 (fr) * 1994-02-14 1996-05-31 Sanofi Elf Dérivés de 3-acylamino-5-phényl-1,4-benzodiazépin-2-one polysubstitués, leur procédé de préparation et les compositions pharmaceutiques les contenant.
WO1995031034A2 (en) * 1994-05-06 1995-11-16 Philips Electronics N.V. Microwave transmission system
DK1221440T3 (da) 1994-06-15 2007-09-17 Otsuka Pharma Co Ltd Benzoheterocykliske derivater der er nyttige som vasopressin- eller oxytocinmodulatorer
JP2926335B2 (ja) * 1997-06-13 1999-07-28 大塚製薬株式会社 医薬組成物
EP1000059B1 (en) * 1997-07-30 2004-09-29 Wyeth Tricyclic vasopressin agonists
JP4338305B2 (ja) * 1997-07-30 2009-10-07 ワイス 三環系バソプレシンアゴニスト
ES2216579T3 (es) 1998-10-09 2004-10-16 Janssen Pharmaceutica N.V. Derivados de 4,5-dihidro-isoxazol y su uso farmaceutico.
GB2355454A (en) 1999-10-20 2001-04-25 Ferring Bv Antidiuretic agents
GB0000079D0 (en) 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
GB0015601D0 (en) 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents
DE10033337A1 (de) 2000-07-08 2002-01-17 Boehringer Ingelheim Pharma Biphenylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
GB0120051D0 (en) 2001-08-16 2001-10-10 Ferring Bv Oxytocin agonists
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
EP1449844A1 (en) 2003-02-14 2004-08-25 Ferring B.V. benzamide derivatives as oxytocin agonists and vasopressin antagonists
EP1627876A1 (en) 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
US7341963B2 (en) * 2005-05-17 2008-03-11 Milliken & Company Non-woven material with barrier skin

Also Published As

Publication number Publication date
EP1248784B1 (en) 2007-07-11
US20030087892A1 (en) 2003-05-08
WO2001049682A1 (en) 2001-07-12
GB0000079D0 (en) 2000-02-23
CN1392875A (zh) 2003-01-22
US7074781B2 (en) 2006-07-11
AU2384601A (en) 2001-07-16
ATE366730T1 (de) 2007-08-15
EE200200367A (et) 2003-12-15
DK1248784T3 (da) 2007-10-29
US20080261951A1 (en) 2008-10-23
JP2006137767A (ja) 2006-06-01
MXPA02006546A (es) 2002-12-09
AU777538B2 (en) 2004-10-21
NO20023137D0 (no) 2002-06-27
AR035327A1 (es) 2004-05-12
SK9112002A3 (en) 2003-01-09
HRP20020481A2 (en) 2004-08-31
KR20020063191A (ko) 2002-08-01
SI1248784T1 (sl) 2007-12-31
NO322571B1 (no) 2006-10-30
PL355808A1 (en) 2004-05-17
PL211341B1 (pl) 2012-05-31
US20060154916A1 (en) 2006-07-13
RU2002120798A (ru) 2004-01-10
ZA200205180B (en) 2004-02-05
PT1248784E (pt) 2007-10-02
MY140467A (en) 2009-12-31
US7560454B2 (en) 2009-07-14
EP1248784A1 (en) 2002-10-16
HK1046910A1 (en) 2003-01-30
CA2396277A1 (en) 2001-07-12
HK1046910B (en) 2007-08-31
HRP20020481B1 (hr) 2009-03-31
NO20023137L (no) 2002-06-27
JP2003519228A (ja) 2003-06-17
JP3813629B2 (ja) 2006-08-23
CZ303444B6 (cs) 2012-09-19
HUP0203917A2 (hu) 2003-03-28
KR100605466B1 (ko) 2006-07-28
CZ20022305A3 (cs) 2002-10-16
UA73152C2 (en) 2005-06-15
UY26521A1 (es) 2001-03-16
CA2396277C (en) 2012-03-20
BR0107414A (pt) 2002-10-08
JP3869723B2 (ja) 2007-01-17
HU229937B1 (hu) 2015-01-28
DE60129298T2 (de) 2008-01-03
IL149528A0 (en) 2002-11-10
SK287005B6 (sk) 2009-09-07
CY1108034T1 (el) 2013-09-04
BR0107414B1 (pt) 2014-09-16
NZ518803A (en) 2003-03-28
DE60129298D1 (de) 2007-08-23
ES2288923T3 (es) 2008-02-01
HUP0203917A3 (en) 2004-07-28
RU2259367C2 (ru) 2005-08-27

Similar Documents

Publication Publication Date Title
CN1183129C (zh) 作为加压素激动剂的稠合氮杂�
CN1589269A (zh) 杂1,2－二氢化茚:一类新型有效的大麻配体
CN1492852A (zh) 作为fsad的nep抑制剂的n-苯丙基环戊基取代的戊二酰胺衍生物
CN1192144A (zh) 1h－4(5)－取代的咪唑衍生物
CN101035790A (zh) (1s,5s)－3－(5,6－二氯代吡啶－3－基)－3,6－二氮杂二环[3.2.0]庚烷苯磺酸盐
CN1387526A (zh) 作为cgrp拮抗剂的新环丙烷、包含该化合物的药物及其生产方法
CN1910164A (zh) 有机化合物
CN1144788C (zh) 双环血管加压素激动剂
CN1956978A (zh) 作为肥大细胞类胰蛋白酶抑制剂的[4－(5－氨基甲基－2－氟－苯基) －哌啶－1－基] －(4－溴－3－甲基－5－丙氧基－噻吩－2－基)-甲酮盐酸盐
CN1449386A (zh) 作为血管升压素拮抗剂的非肽取代的螺苯并氮杂䓬
CN1056102A (zh) 新的哒嗪及其制备方法
CN1238766A (zh) 3－烷氧基异噁唑－4－基－取代的－2－氨基羧酸化合物
CN1092074A (zh) 二氮杂䓬衍生物
CN1399638A (zh) 用作加压素受体拮抗剂的吲哚并氮杂䓬
CN1148809A (zh) 眼压降低剂
CN1072413A (zh) 氨基酸衍生物
US5109136A (en) Tetracyclic amines useful as cerebrovascular agents
HK1101076A (en) [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone hydrochloride as an inhibitor of mast cell tryptase
CN1481379A (zh) 作为ccr-3受体拮抗剂的取代的吡咯烷
HK1018048A1 (en) Benzimidazole compounds and their use as modulators of the gaba(a) receptor complex
HK1018048B (en) Benzimidazole compounds and their use as modulators of the gaba(a) receptor complex

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20090116

Address after: British Southampton

Patentee after: Vantia Ltd.

Address before: Holland Hoofddorp

Patentee before: Ferring BV

ASS Succession or assignment of patent right

Owner name: WANTIYA CO., LTD.

Free format text: FORMER OWNER: FEHLING STOCK CO., LTD.

Effective date: 20090116

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050105

Termination date: 20200104

CF01 Termination of patent right due to non-payment of annual fee